Heart disease

MHRA
#AstraZeneca #Cardiovascular disease #Heart disease #MHRA

UK licence extension approved for AstraZeneca’s dapagliflozin

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin for the treatment of symptomatic chronic heart failure (HF).  The drug is approved in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and… Read More

#News #Regulatory

#British Heart Foundation (BHF) #CRISPR #Gene editing #Heart disease #University of Oxford

International researchers win £30m for work in treating heart conditions  

An international team of researchers has won £30 million for its work in developing a potential cure for inherited heart muscle conditions in young people.  CureHeart was selected as the winner of the British Heart Foundation’s (BHF) Big Beat Challenge, which grants a £30 million non-commercial grant… Read More

#News

#Biopharmaceuticals #Heart disease

Sweet talk: “sugar soap” reverses blocked arteries 

Australian biopharmaceutical company Cholrem have produced CAVADEX (Beta-Cyclodextrin), a product which removes cholesterol from damaged and narrowed arteries after a few months of treatment, leading to increased blood flow.  Context Atherosclerosis, also known as heart disease, is reportedly the western world’s number one killer of people. This disease results… Read More

#News #Trending News